TR200400621T2 - GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. - Google Patents

GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Info

Publication number
TR200400621T2
TR200400621T2 TR2004/00621T TR200400621T TR200400621T2 TR 200400621 T2 TR200400621 T2 TR 200400621T2 TR 2004/00621 T TR2004/00621 T TR 2004/00621T TR 200400621 T TR200400621 T TR 200400621T TR 200400621 T2 TR200400621 T2 TR 200400621T2
Authority
TR
Turkey
Prior art keywords
gdf
methods
vaccination
analogs
homologous
Prior art date
Application number
TR2004/00621T
Other languages
English (en)
Turkish (tr)
Inventor
Halkier Torben
Mouritsen S�ren
Klysner Steen
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of TR200400621T2 publication Critical patent/TR200400621T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Control Of Eletrric Generators (AREA)
TR2004/00621T 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. TR200400621T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26

Publications (1)

Publication Number Publication Date
TR200400621T2 true TR200400621T2 (tr) 2004-08-23

Family

ID=26065065

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/00621T TR200400621T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
TR2002/00133T TR200200133T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/00133T TR200200133T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Country Status (21)

Country Link
US (2) US7070784B1 (https=)
EP (1) EP1200119A2 (https=)
JP (1) JP2003506325A (https=)
KR (1) KR100750695B1 (https=)
CN (1) CN1384757A (https=)
AU (1) AU778470B2 (https=)
CA (1) CA2379852A1 (https=)
EA (1) EA005248B1 (https=)
EE (1) EE200200025A (https=)
HK (1) HK1048937A1 (https=)
HR (1) HRP20010900A2 (https=)
HU (1) HUP0201861A3 (https=)
IL (1) IL146845A0 (https=)
MX (1) MXPA01013232A (https=)
NO (1) NO20016252L (https=)
NZ (1) NZ517058A (https=)
PL (1) PL353855A1 (https=)
SK (1) SK722002A3 (https=)
TR (2) TR200400621T2 (https=)
WO (1) WO2001005820A2 (https=)
ZA (1) ZA200109901B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
EP1699820A2 (en) * 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP1799709B1 (en) 2004-09-30 2012-04-04 ORICO Limited Myostatin isoform
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
CN101522707B (zh) 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CN103249835B (zh) * 2011-07-06 2015-05-20 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因座位及其应用
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240366760A1 (en) * 2023-01-17 2024-11-07 Regen BioPharma, Inc. Activation of survivin-specific immune responses using dendritic cell derived exosomes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
CN1178955C (zh) 1997-04-15 2004-12-08 法默卡有限公司 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
AU756620B2 (en) * 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
CA2315256A1 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
KR20020026544A (ko) 2002-04-10
ZA200109901B (en) 2003-05-28
KR100750695B1 (ko) 2007-08-22
TR200200133T2 (tr) 2002-05-21
WO2001005820A3 (en) 2001-07-19
EP1200119A2 (en) 2002-05-02
EE200200025A (et) 2003-04-15
MXPA01013232A (es) 2005-05-24
HK1048937A1 (zh) 2003-04-25
NO20016252D0 (no) 2001-12-19
IL146845A0 (en) 2002-07-25
EA200200182A1 (ru) 2002-06-27
NZ517058A (en) 2004-04-30
AU5967500A (en) 2001-02-05
WO2001005820A2 (en) 2001-01-25
CN1384757A (zh) 2002-12-11
PL353855A1 (en) 2003-12-01
HRP20010900A2 (en) 2003-08-31
HUP0201861A3 (en) 2004-07-28
US7056512B1 (en) 2006-06-06
US7070784B1 (en) 2006-07-04
JP2003506325A (ja) 2003-02-18
EA005248B1 (ru) 2004-12-30
CA2379852A1 (en) 2001-01-25
AU778470B2 (en) 2004-12-09
SK722002A3 (en) 2003-02-04
NO20016252L (no) 2002-03-15
HUP0201861A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
TR200400621T2 (tr) GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
NO20023961D0 (no) Ny fremgangsmåte for nedregulering av amyloid
BenMohamed et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses
EP1108035B1 (en) Treatment of cervical cancer
MXPA02007796A (es) Metodo novedoso para la disminucion de cuerpos amiloides.
RU2010138815A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
US20220378895A1 (en) Novel immunogens and methods for discovery and screening thereof
TR200100936T2 (tr) Terapötik aşılama
CA2325566A1 (en) Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
JP2011168611A (ja) 髄膜炎菌類タンパク質ｎｍｂ１８７０のドメインおよびエピトープ
CA2457140A1 (en) Beta-amyloid-analogue - t-cell epitope vaccine
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
JPH03173830A (ja) ワクチン組成物
JPH10500128A (ja) マイコバクテリア感染症に対するワクチン
EP1266662A2 (en) Synthetic peptide vaccines for dental caries
JP3881514B2 (ja) クラミジア感染症に対するｄｎａ免疫化
JP2002542264A (ja) 核酸による免疫化
CA2082425A1 (en) Vaccine compositions
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
JP2002538169A (ja) インフルエンザ菌に起因する疾患を防御するための、少なくとも３つの抗原を含む多成分系ワクチン
EP1502602A3 (en) Methods for therapeutic vaccination
MY135691A (en) Method for down-regulation of gdf-8 activity
WO2004069163A2 (en) Cross-protective epitopes of moraxella catarrhalis and use thereof
ECSP003580A (es) Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8